Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Greene

Orthopaedic Surgery Yakima, WA Medical Doctor

NPI 1952350639 CMS profile 43573

111 S 11Th Ave Ste 320, Yakima, WA 98902

Open in the dashboard

General payments

$10,787

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Greene of Yakima, WA is reported in the CMS Open Payments database as having received $10,787 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $750 15
2024 General $862 15
2023 General $2,392 23
2022 General $1,542 28
2021 General $1,720 42
2020 General $485 12
2019 General $3,036 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Greene
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Robert Greene were reported at $750. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Robert Greene Orthopaedic Surgery median Middle half National median
2019 $3,036 $644 $140–$2,844 $163
2020 $485 $312 $75–$1,860 $114
2021 $1,720 $520 $117–$2,495 $132
2022 $1,542 $598 $128–$2,731 $149
2023 $2,392 $461 $128–$2,264 $160
2024 $862 $497 $134–$2,475 $164
2025 $750 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $6,992 152 payments
  2. Encore Medical, LP $1,856 9 payments
  3. Pacira Pharmaceuticals Incorporated $1,697 6 payments
  4. Medacta USA, Inc. $133 2 payments
  5. Heron Therapeutics, Inc. $40 2 payments
  6. Boston Scientific Corporation $26 1 payment
  7. Amniox Medical, Inc. $20 1 payment
  8. Sanofi Pasteur Inc. $12 1 payment
  9. KCI USA, Inc $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,599 169 payments
  2. Honoraria $1,500 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,000 1 payment
  4. Travel and Lodging $463 3 payments
  5. Consulting Fee $225 1 payment
Products named General payments · program years 2019–2025
  1. MAKO Knees, Hips $2,501 53 payments
  2. EXPAREL $1,697 6 payments
  3. MAKO Knees, Hips $800 16 payments
  4. None $610 13 payments
  5. DJO SURGICAL $282 5 payments
  6. BIO4 $251 10 payments
  7. PANGEA $150 3 payments
  8. GAMMA $134 5 payments
  9. MOTO UNI $133 2 payments
  10. TRITANIUM $98 4 payments
  11. Other $1,384 54 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

637

Median for Orthopedic Surgery: 203

Drug cost

$7,779

Median for Orthopedic Surgery: $1,433

Branded share of claims

6.8%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $5,001
Oxycodone Hcl Generic 185 $910
Omeprazole Generic 78 $533
Ondansetron Odt Ondansetron Brand 31 $303
Methylprednisolone Generic 24 $293
Cephalexin Generic 119 $277
Amoxicillin Generic 82 $128
Meloxicam Generic 34 $124
Hydroxyzine Pamoate Generic 13 $73
Tramadol Hcl Generic 31 $56

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$283,362

Of which drugs: $36,020

Medicare patients

400

Average age 76

Services billed

8,341

255 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Diabetes 22%
Depression 19%
Ischemic heart disease 18%
Chronic kidney disease 18%
Atrial fibrillation 17%
Osteoporosis 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 28 1,600 $21,858
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 21 1,542 $10,803
Injection, methylprednisolone acetate, 1 mg J1010 Office 39 4,041 $418
Injection, methylprednisolone acetate, 80 mg J1040 Office 20 25 $154

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record